After the Phase 2b clinical trial named Abili-T achieved full enrollment with 190 secondary progress multiple sclerosis (SPMS) patients, The Woodlands, Texas-based Opexa Therapeutics is patiently awaiting results for the company’s lead candidate, Tcelna, which are expected in the second half of 2016.

Genzyme presented new magnetic resonance imaging (MRI) data from the Lemtrada® (alemtuzumab) clinical development program on April 23, 2015, at the 67th American Academy of Neurology (AAN) Annual Meeting. The company showed that in the extension phase of two Phase III trials (years 3 and 4), the drug continued to protect the nervous…

Biogen plans to present new clinical data at the 67th American Academy of Neurology (AAN) Annual Meeting in Washington D.C., April 18 – 25, 2015, including numerous presentations focusing on multiple sclerosis.  In a company press release, Biogen stated “At AAN, we will feature new scientific data, including research highlighting the…

Biopharmaceutical company Receptos, Inc. has enrolled the first participant with relapsing multiple sclerosis (RMS) in its SUNBEAM phase 3 trial, which will evaluate the potential therapy RPC1063 in patients who suffer from the disease. The company’s phase 3 RADIANCE trial, also…

The Scottish Medicines Consortium has just approved Biogen Idec’s Plegridy (peg interferon beta-1a) for the treatment of relapsing multiple sclerosis (MS) in patients between 18 to 65 years old, making the Consortium the first United Kingdom-based regulatory body to endorse the disease-modifying drug on the…

Canada has one of the world’s highest Multiple Sclerosis (MS) prevalence rates. Some 100,000 Canadians live with the disease, and three people are newly diagnosed each day. Most people are diagnosed with relapsing MS in their twenties and thirties, and MS is the most common neurological disease affecting young adults…

Results from a Phase 3 clinical trial entitled “AVANCE” revealed promising clinical outcomes in patients with relapsing-remitting multiple sclerosis treated for one year with peg interferon beta-1a. The analysis was published in the journal BMC Neurology, in a study entitled “Effect of peg interferon beta-1a on MRI measures and…

Immunosupressive therapy in combination with hemotopoietic cell transplant was found to induce remission of Multiple Sclerosis activity for up to 3 years. The new findings could usher in a new mode of effective treatment for MS that could greatly improve quality of life for those with the disease and…

Biopharmaceutical company Receptos, Inc. is enrolling the first patient in their SUNBEAM phase 3 trial to evaluate the company’s investigational therapy for the treatment of patients with relapsing multiple sclerosis (RMS) and ulcerative colitis (UC), called RPC1063. In addition, Receptos has recently started its phase 3 …

Mapi Pharma Ltd., a development stage pharmaceutical company specializing in the development of high-barrier to entry and high-added value generic drugs, announced it has treated the first patient in the Phase IIa study of GA Depot for relapsing-remitting multiple sclerosis (RRMS). Lead investigator Professor Ariel Miller, M.D., Ph.D., Head of the Multiple Sclerosis & Brain…

A team of researchers from the Case Western Reserve’s Frances Payne Bolton School of Nursing has designed a 24-week exercise program tailored specifically for patients with multiple sclerosis (MS) in varying states of disease progression. The program drew inspiration and structure from a series of informational pamphlets…

Israel-based biopharmaceutical company Teva Pharmaceutical Industries Ltd. announced last week that its thrice-weekly COPAXONE® (glatiramer acetate) 40mg/ml treatment for relapsing-remitting multiple sclerosis (RRMS) has received positive results in a decentralized procedure. The favorable outcome proceeds a Positive Assessment Report from the United Kingdom, the Reference Member…

Neurology and autoimmune therapeutics company GeNeuro SA has just announced the formation of a partnership with independent French pharmaceutical company Servier for the co-development and marketing of GNbAC1 for Multiple Sclerosis (MS). It is the first humanized monocloncal antibody treatment formulated to address one of this disease’s causal factors, making it…

Genzyme, a Sanofi company with over 30 years of dedication to researching and developing novel treatments for rare and orphan diseases, has just announced the Alberta Drug Program has finally decided to include Aubagio® (teriflunomide) 14mg in the provincial drug formulary, indicated for the first-line…

Teva Pharmaceutical Industries Ltd., the company that developed the injectable multiple sclerosis treatment Copaxone (Glatiramer acetate),  has announced their pursuit of regulatory approval in Japan. This development comes a year after signing an agreement with Takeda Pharmaceutical Co. Ltd. According to a…

A member of the musical Osmond family, David Osmond, recently released a music video for his inspirational song “I Can Do This.” He has dedicated it to men and women all over the world who are faced with challenges that make them doubt their abilities and self-worth, but the real…

New Zealand-based Pharmaceutical Management Agency (PHARMAC) has approved the funding of new treatments for multiple sclerosis (MS), which are expected not only to reach more patients, but also be more effective in curtailing the disease’s progressive symptoms. The therapies currently funded are meant for the treatment of …

Now more than ever, groundbreaking, new therapies for chronic diseases and infections come with high price tags. Earlier in the year, Gilead Sciences’ drug Sovaldi for Hepatitis C, as well as Vertex’s Kalydeco for Cystic Fibrosis, both raised eyebrows over their cost. Now, a new MS therapy is doing the…

Genzyme, a Sanofi company, has announced that the Canadian province of Québec’s Institut national d’excellence en santé et services sociaux (INESSS) has recommended that the company’s multiple sclerosis (MS) drug Lemtrada (alemtuzumab) 12 mg be included on the provincial drug formulary under “Médicament d’exception” as a second-line treatment for…

Recent research reveals that placenta-based cell therapy is both safe and effective for treating both Relapsing-Remitting and progressive forms of MS. A new study entitled “Human Placenta-Derived Cells (PDA-001) for the Treatment of Adults With Multiple Sclerosis: A Randomized, Placebo-Controlled, Multiple-Dose Study” and published in August…

A new study, entitled “The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis” published online in JAMA Neurology, reports the effect of Glatiramer acetate therapy on B cells in relapsing-remitting multiple sclerosis (MS) patients. This first-of-its-kind study could…

Deepelling International conferences on multiple sclerosis (MS) typically gather the most accomplished experts and leading biotech companies under one roof to exchange discoveries and celebrate new hope for MS patients all over the world. Quebec is one of North America’s epicenters for MS research and developments. This year, on…

For the first time, an antisense oligonucleotide has been shown to be effective in treating relapse-remitting multiple sclerosis. A phase 2a clinical trial of Antisense Therapeutics Limited’s ATL1102, a CD49d antisense drug, showed that the treatment quickly reduced brain lesions in RRMS patients following the start of therapy.

Biogen Idec revealed data from its second year of the phase 3 ADVANCE clinical trial for the study of Plegridy as a treatment for patients with relapsing forms of multiple sclerosis, which demonstrated the positive effects of the subcutaneous injectable therapy beyond the first year…

During the 30th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) last week in Boston, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), together with Active Biotech (NASDAQ OMX NORDIC:ACTI), presented new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS)…

Biogen Idec presented the five-year results from its ENDORSE phase 3 extension study of Tecfidera (dimethyl fumarate), which revealed that the treatment is able to provide strong and sustained efficacy to patients with relapsing-remitting multiple sclerosis (RRMS), at last week’s ACTRIMS-ECTRIMS summit. Not only did…

Those attending this week’s ACTRIMS-ECTRIMS convention set to take place on the 10th of September until the 13th in Boston, can expect Swiss pharmaceutical company Novartis to present promising findings on Gilenya (fingolimod) — the company’s leading oral formulation for relapsing-remitting multiple sclerosis (RRMS). In previously completed studies and clinical trials,…

A dynamic research team composed of doctors and scientists recently completed and published a study that sought to gain a better understanding of walking impairment, as it is manifested in patients living with multiple sclerosis (MS), a neurodegenerative disease wherein the impulse-conducting myelin sheath is attacked by the body’s own…

As researchers continue to develop a clearer understanding of the underlying causes of multiple sclerosis (MS), it is becoming increasingly apparent that the future of treating the disease is likely to center on neural protection and a reversal of the demyelination process that strips away the critical insulation…

Biogen Idec, a biotechnology company focused on developing innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders, has announced that the U.S. Food and Drug Administration (FDA) has approved PLEGRIDYTM (peginterferon beta-1a), a new treatment for people with relapsing forms of multiple sclerosis…